Recombinant Designer Collagens for Safe Biomaterials
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current collagen biomaterials derived from animal sources pose risks of immunogenicity and contamination, and recombinant collagens produced in existing systems face challenges such as high costs and low yields, along with molecular properties that can cause adverse reactions.
Innovation Solution
Development of recombinant synthetic collagens with a triple helical backbone produced in a prokaryotic expression system, incorporating biologically active sequences for specific functions, such as integrin binding motifs, to create 'designer' collagens that are scalable, cost-effective, and customizable.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If collagen biomaterials are derived from animal sources, then they provide natural collagen structure and function, but they pose risks of immunogenicity and contamination
Solution Approach 1:
The patent creates synthetic collagen molecules that copy the essential triple-helical structure and functional domains (such as GFOGER motifs) of natural collagen without using animal-derived materials. This allows the biomaterial to maintain collagen's beneficial properties while eliminating immunogenicity and contamination risks associated with animal sources
Solution Approach 2:
The invention employs synthetic peptide sequences that can be produced recombinantly or chemically, replacing expensive and potentially hazardous animal-derived collagen. These synthetic alternatives provide a safer, more controlled, and scalable source of collagen-like structures for biomedical applications
2Reliability
If recombinant collagens are produced in existing systems, then they reduce immunogenicity, but they face challenges of high costs and low yields
Solution Approach 1:
The patent extracts only the essential functional elements of collagen (the triple-helical backbone and specific cell-binding motifs like GFOGER) and produces them as simplified recombinant proteins or synthetic peptides. This extraction approach reduces production complexity and cost while maintaining the key functions needed for biomaterial applications
Solution Approach 2:
The collagen molecule is segmented into its core functional components: a triple-helical structural domain and separate cell-binding motifs. These segments can be produced independently through recombinant expression in bacterial or insect systems, then assembled or used separately, improving production efficiency and reducing costs compared to producing full-length native collagen
3Adaptability or versatility
If native collagen molecular properties are used, then they provide natural structure and function, but they can cause adverse reactions
Solution Approach 1:
The patent applies local quality by incorporating cell-binding motifs (such as GFOGER sequences) at specific locations within the synthetic collagen structure, while the rest of the molecule uses simplified or modified sequences. This allows the biomaterial to provide natural-like cell interaction functions only where needed, reducing unnecessary immunogenic elements elsewhere in the structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The designer collagens demonstrate enhanced binding capabilities to integrins, support cell adherence and spreading, and are non-thrombogenic, offering improved safety and efficacy as biomaterials with reduced immunogenicity and production costs.
Implementation Method 1
The integrins are a family of heterodimeric cell surface receptors involved in cell-cell and cell-substrate adhesion. They act as bridging molecules that link intracellular signaling molecules to the extracellular matrix through bi-directional signaling
Data Source
AI summary
The present invention identified a recombinant synthetic collagen containing a triple helical backbone protein produced in a prokaryotic expression system where the protein contains at least one ‘inserted’ biologically active sequence(s).